[18F]FDG
[18F]FDG is a pharmaceutical drug with 65 clinical trials. Currently 23 active trials ongoing. Historical success rate of 85.7%.
Success Metrics
Based on 18 completed trials
Phase Distribution
Phase Distribution
22
Early Stage
11
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
81.8%
18 of 22 finished
18.2%
4 ended early
23
trials recruiting
65
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Application and Comparison of [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI in Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
Clinical Trials (65)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Application and Comparison of [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI in Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
EXPLORER Total Body PET/CT Imaging for Myofascial Pain
Single-tracer Multiparametric PET Imaging
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
PD-L1 Specific 68Ga-THP-PD-L1-3 Probe for PET Imaging in Solid Tumors
The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 65